53 results
8-K
EX-99.1
RCUS
Arcus Biosciences Inc
19 Jul 21
Departure of Directors or Certain Officers
4:47pm
on Arcus’s combinatorial development strategy and placed the company in strong position to fully leverage the opportunities inherent in its five clinical … of the strategy, design and execution associated with Arcus’s broad array of clinical trials and has assumed increasing responsibilities since December of last
8-K/A
RCUS
Arcus Biosciences Inc
29 Mar 19
Departure of Directors or Certain Officers
12:00am
, with responsibility for corporate strategy and development, investor and media relations, corporate communications, finance and strategic marketing. From … , a biotechnology company, with responsibility for corporate strategy, corporate development, finance, investor relations and G&A operations. From November
8-K
RCUS
Arcus Biosciences Inc
25 Mar 19
Results of Operations and Financial Condition
4:15pm
, with responsibility for corporate strategy and development, investor and media relations, corporate communications, finance and strategic marketing. From … , a biotechnology company, with responsibility for corporate strategy, corporate development, finance, investor relations and G&A operations. From
8-K
EX-99.1
RCUS
Arcus Biosciences Inc
2 Nov 22
Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update
4:05pm
a broad development strategy for their anti-TIGIT antibody domvanalimab in lung cancer, which now includes three ongoing registrational Phase 3 trials … in multiple non-small cell lung cancer (NSCLC) settings; as part of this strategy, the companies have amended the study design of ARC-10
8-K
EX-99.1
RCUS
Arcus Biosciences Inc
5 May 20
Arcus Biosciences Announces First Quarter 2020 Financial Results and Corporate Updates
4:15pm
the advancement of our regulatory strategy.”
Recent Key Highlights
Received U.S. Food & Drug Administration (FDA) clearance of an Investigational New … cancer
Anticipated Corporate Milestones
Initiation of enrollment in ARC-6, a Phase 1b/2 platform trial expanding our strategy in prostate cancer
8-K
EX-99.1
ydqdv4nqphyny0r372
5 Mar 20
Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates
4:14pm
8-K
EX-99.1
ovm rporj98y4maf6
5 Nov 20
Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates
4:16pm
10-K
ehylhhd
5 Mar 19
Annual report
12:00am
424B5
54mkkobbg3y7xxki4
26 Apr 19
Prospectus supplement for primary offering
4:58pm
DEF 14A
w4tkms
22 Apr 19
Definitive proxy
4:37pm
8-K
EX-99.1
o2t542u64lb3tf4xg
23 Feb 22
Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
4:08pm